Boulder-based Clovis sees stock surge as FDA approves accelerated review of ovarian cancer drug

Boulder Daily Camera – Shares of Boulder-based Clovis Oncology (NASDAQ: CLVS) were up on news that the Food and Drug Administration accepted the drug maker’s application for an accelerated review of its advanced ovarian cancer drug, rucaparib. Learn more.